How to read common telehealth claims against what they actually mean.
• “LegitScript-certified” — a verifiable third-party status about advertising/operations, not FDA approval.
• “Licensed pharmacy” — expected baseline, not a quality differentiator on its own.
• “Third-party tested” — ask to see the results for your batch.
| What to know |
|---|
| “LegitScript-certified” — a verifiable third-party status about advertising/operations, not FDA approval. |
| “Licensed pharmacy” — expected baseline, not a quality differentiator on its own. |
| “Third-party tested” — ask to see the results for your batch. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.